Clarification of the Scope and Requirements of PAR-11-150, Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)"

Notice Number: NOT-CA-11-011

Release Date: April 19, 2011

National Cancer Institute (NCI)

The purpose of this Notice is to clarify specific issues pertinent to the scientific scope and requirements of PAR-11-150 entitled Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01)".

Re: Section I. Funding Opportunity Description, 1. Research Objectives.

• Whereas the primary emphasis of PAR-11-150 is on the evaluation of responses to therapy, research projects involving quantitative imaging for prediction of therapeutic responses are also appropriate.
• Testing of quantitative imaging tools in Phase 3 clinical trials can be included for their validation as clinical decision-making tools.
• All references to PAR-07-214 are changed to reference PAR-10-169.

Re: Section VI. Award Administration Information, 2. Administrative and National Policy Requirements, Cooperative Agreement Terms and Conditions of Award

• Awardees reporting the results for the quantitative imaging tools tested for performance in therapeutic clinical trials will NOT be required to disclose the identities of specific therapeutic agents being used in these clinical trials.

All other aspects of the FOA remain unchanged.

Please direct all inquiries to:

Robert J. Nordstrom, Ph.D.
Cancer Imaging Program
National Cancer Institute
6130 Executive Boulevard, EPN Room 6071, MSC 7412
Bethesda, MD 20892-7412 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 301 594-9121
Fax: 301 480-3507
E-mail: [email protected]

James Deye, Ph.D.
Radiation Research Program
National Cancer Institute
6130 Executive Boulevard, EPN Room 6018, MSC 7440
Bethesda, MD 20892-7440 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for non-USPS delivery)
Telephone: 310 496-6276
Fax: 301 480-5785
E-mail: [email protected]